A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to B-cell Lymphoma
Related studies linked through entity extraction aliases.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
FT516 in Subjects With Advanced Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Study of TG-1801 in Subjects With B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
- Status
- RECRUITING
- Phase
- NA
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
- Status
- COMPLETED
- Phase
- PHASE1
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL
- Status
- UNKNOWN
- Phase
- PHASE1